1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, S Tarran Jones, Ted A Yednock: Humanized antibodies against leukocyte adhesion molecule VLA-4. Athena Neurosciences, Townsend & Townsend & Crew, November 24, 1998: US05840299 (84 worldwide citation)


The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


2
Dale B Schenk, Peter A Seubert, Carmen Vigo Pelfrey: Methods for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, January 14, 1997: US05593846 (182 worldwide citation)


Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


3
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Methods for monitoring cellular processing of .beta.-amyloid precursor protein. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, August 15, 1995: US05441870 (130 worldwide citation)


Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diag ...


4
Michael G Schlossmacher, Dennis J Selkoe: Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, June 16, 1998: US05766846 (126 worldwide citation)


Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


5
Lisa C McConlogue, Jun Zhao: Transgenic animals harboring APP allele having swedish mutation. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, March 18, 1997: US05612486 (124 worldwide citation)


The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


6
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP. Athena Neurosciences, Eli Lilly and Company, John Storella, Jean Duvall, February 24, 1998: US05721130 (93 worldwide citation)


Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble .beta.APP fragment resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. In vivo monitoring of secretion of the .beta.APP fragment may be monitored for diag ...


7
Becker Gerald Wayne, Brems David Nettleship, Chaney Michael Owen, May Patrick Cornelious, Rydel Russel Eugene, Simmons Linda Karen, Tomaselli Kevin James: Pharmaceutical screens and antibodies.. Lilly Co Eli, Athena Neurosciences, August 31, 1994: EP0613007-A2 (88 worldwide citation)


This invention describes a series of assays useful in evaluating the efficacy of agents which inhibit the neurotoxic effects of beta -amyloid peptide. These assays employ beta -amyloid peptide which is in a predominantly beta -sheet conformation. This invention also encompasses antibodies having a s ...


8
Dale B Schenk, Michael G Schlossmacher, Dennis J Selkoe, Peter A Seubert, Carmen Vigo Pelfrey: Methods and compositions for the detection of soluble .beta.-amyloid peptide. Athena Neurosciences, Eli Lilly and Company, Brigham and Women s Hospital, Townsend and Townsend and Crew, November 17, 1998: US05837672 (81 worldwide citation)


Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compoun ...


9
Susanna M S Chrysler, Sukanto Sinha, Pamela S Keim, John P Anderson: .beta.-secretase. Athena Neurosciences, Townsend and Townsend and Crew, April 28, 1998: US05744346 (79 worldwide citation)


Compositions comprising a novel protease capable of cleaving .beta.-amyloid precursor protein on the amino-terminal side of the .beta.-amyloid peptide therein are provided. The protease is designated .beta.-secretase. The .beta.-secretase may be used in screening assays to identify .beta.-secretase ...


10
Peter A Seubert, Dale B Schenk, Lawrence C Fritz: Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein. Athena Neurosciences, Eli Lilly and Company, Jean M Duvall, John R Storella, February 25, 1997: US05605811 (74 worldwide citation)


The present invention provides methods for identifying beta amyloid production inhibitors, wherein cells are cultured under conditions which result in secretion of a soluble fragment of beta amyloid precursor protein. The amino acid sequence of the fragment extends from the amino terminus of beta AP ...



Click the thumbnails below to visualize the patent trend.